NEW YORK, December 19, 2025 – BioMarin’s $4.8 billion acquisition of Amicus Therapeutics, announced this morning, signals a major strategic shift for the biotechnology company and a bold bet that Wall Street has been anticipating.
A New Chapter for BioMarin
The deal represents a significant move for BioMarin, particularly after setbacks with its hemophilia gene therapy.
- BioMarin is acquiring Amicus for $4.8 billion.
- The deal includes two approved drugs for Pompe and Fabry diseases, generating $600 million in annual revenue.
- BioMarin CEO Alexander Hardy promised strategic deals after taking the helm.
- Shares of BioMarin rose 18% in morning trading following the announcement.
- Earlier this year, BioMarin purchased Inozyme for $270 million.
Alexander Hardy, who became CEO of BioMarin after succeeding Jean Jacques Bienaime, has been under pressure to deliver growth. Since his appointment, BioMarin’s stock price had declined by more than a third due to commercial disappointments with its hemophilia gene therapy, which the company is now attempting to license to another firm. Hardy explicitly told investors to expect deals, and subsequently hired James Sabry, a business development executive from Genentech, to spearhead those efforts.
What’s driving BioMarin’s acquisition strategy? The company is clearly looking to diversify its portfolio and bolster its revenue streams with established products, rather than relying solely on the success of novel therapies. This acquisition provides immediate financial stability and a foothold in the rare disease market.
The acquisition will bring two approved therapies into BioMarin’s portfolio: one for Pompe disease and another for Fabry disease, collectively generating $600 million in annual revenue. Investors reacted positively to the news, with BioMarin shares jumping 18% in morning trading – an unusual outcome, as acquiring companies often see their stock dip upon deal announcements. This positive reaction suggests confidence in Hardy’s strategy and the potential synergies between the two companies.
Did you know? BioMarin previously acquired manufacturing firm Inozyme for $270 million earlier this year, demonstrating a proactive approach to strategic investments.
Hardy spoke with reporters Friday morning about the deal, emphasizing the strategic fit and long-term value it brings to BioMarin. The conversation, edited for clarity and length, highlighted the company’s commitment to the rare disease space and its ambition to become a leader in the field.
